IQVIA Holdings (LTS:0JDM) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0JDM IQVIA Holdings Inc LTS:0JDM
85 GF Score
Price $206.23
GF Value $249.98
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is IQVIA Holdings 5-Year Yield-on-Cost %?

IQVIA Holdings LTS:0JDM -1.57% 85 5-Year Yield-on-Cost % is 0.00 as of Jul. 18, 2026. GuruFocus rates LTS:0JDM with a GF Score™ of 85/100 and a GF Value™ of $249.98 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 64 Medical Diagnostics & Research companies, IQVIA Holdings ranks worse than 1562498.44% on this metric.

IQVIA Holdings's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for IQVIA Holdings's 5-Year Yield-on-Cost % or its related term are showing as below:



LTS:0JDM's 5-Year Yield-on-Cost % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.54
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

IQVIA Holdings  (LTS:0JDM) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


IQVIA Holdings 5-Year Yield-on-Cost % Related Terms


LTS:0JDM vs WAT, ILMN, NTRA: 5-Year Yield-on-Cost % Comparison

For the Diagnostics & Research subindustry, IQVIA Holdings's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IQVIA Holdings 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where IQVIA Holdings's 5-Year Yield-on-Cost % falls into.


LTS:0JDM
85GF Score
IQVIA Holdings Inc LTS:0JDM
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IQVIA Holdings 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of IQVIA Holdings is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
IQVIA Holdings (LTS:0JDM) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 18, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on IQVIA Holdings and its competitors. According to the industry distribution chart, IQVIA Holdings ranks #999999 out of 64 companies in the Medical Diagnostics & Research industry.
Is IQVIA Holdings' 5-Year Yield-on-Cost % too high?
IQVIA Holdings' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, IQVIA Holdings ranks #999999 out of 64 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, IQVIA Holdings has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IQVIA Holdings' 5-Year Yield-on-Cost % compare to WAT and ILMN?
According to the Medical Diagnostics & Research industry distribution chart, IQVIA Holdings ranks #999999 out of 64 companies for 5-Year Yield-on-Cost %. This places IQVIA Holdings in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.54, based on 64 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on IQVIA Holdings and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IQVIA Holdings's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IQVIA Holdings stock overvalued right now?
Based on GuruFocus' analysis, IQVIA Holdings (LTS:0JDM) is currently considered Modestly Undervalued. The stock's GF Value™ is $249.98, compared to a current price of $206.23 — trading 17.5% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. IQVIA Holdings' overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For IQVIA Holdings (LTS:0JDM), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IQVIA Holdings (LTS:0JDM) Overvalued in 2026?

Based on GuruFocus' analysis, IQVIA Holdings stock appears to be undervalued. The current stock price of $206.23 is trading 17.5% below its estimated GF Value™ of $249.98. GuruFocus considers IQVIA Holdings to be Modestly Undervalued.

Key valuation signals for LTS:0JDM:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: $249.98 vs. price of $206.23 (17.5% below fair value)
  • GF Score™: 85/100 with 3 warning signs

No single metric tells the full story. See the LTS:0JDM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


IQVIA Holdings Business Description

Address 2400 Ellis Road, Durham, NC, USA, 27703
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
85GF Score

Get the complete analysis for LTS:0JDM

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$206.23
Price
$249.98
GF Value